EMEA: Guideline on the Clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C
The aim of this guideline is to provide guidance on the clinical development of compounds for the treatment of Chronic Hepatitis C (CHC). It should be read in conjunction with updated and recognized clinical treatment guidelines. The guideline focuses on direct-acting anti-viral agents (DAAs).
The source of the news: http://www.emea.europa.eu/pdfs/human/ewp/3003908enfin.pdf